Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1995 1
1997 3
1998 1
2000 3
2001 1
2002 1
2003 1
2009 1
2010 1
2013 1
2014 4
2015 2
2016 9
2017 4
2018 3
2019 2
2021 2
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, Asgharnejad M, Dlugos D. Hahn CD, et al. Among authors: asgharnejad m. Epilepsia. 2022 Oct;63(10):2671-2683. doi: 10.1111/epi.17367. Epub 2022 Aug 4. Epilepsia. 2022. PMID: 35841234 Free PMC article. Clinical Trial.
Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE).
Demarest S, Jeste S, Agarwal N, Arkilo D, Asgharnejad M, Hsiao S, Thibert R. Demarest S, et al. Among authors: asgharnejad m. Epilepsy Behav. 2023 May;142:109173. doi: 10.1016/j.yebeh.2023.109173. Epub 2023 Apr 1. Epilepsy Behav. 2023. PMID: 37011526 Free article. Clinical Trial.
The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
O'Donnell P, Dong C, Murthy V, Asgharnejad M, Du X, Summerfelt A, Lu H, Xu L, Wendland JR, Dunayevich E, Buhl DL, Litman R, Hetrick WP, Hong LE, Rosen LB. O'Donnell P, et al. Among authors: asgharnejad m. Neuropsychopharmacology. 2023 Jun;48(7):1052-1059. doi: 10.1038/s41386-023-01560-0. Epub 2023 Mar 16. Neuropsychopharmacology. 2023. PMID: 36928351 Free PMC article. Clinical Trial.
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation.
O'Donnell P, Dijkstra FM, Damar U, Quanhong L, de Goede AA, Xu L, Pascual-Leone A, Buhl DL, Zuiker R, Ruijs TQ, Heuberger JAAC, MacMullin P, Lubell M, Asgharnejad M, Murthy V, Rotenberg A, Jacobs GE, Rosen L. O'Donnell P, et al. Among authors: asgharnejad m. Transl Psychiatry. 2021 May 27;11(1):325. doi: 10.1038/s41398-021-01451-2. Transl Psychiatry. 2021. PMID: 34045439 Free PMC article. Clinical Trial.
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers.
Dijkstra F, O'Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, Zuiker R, van Gerven J, Jacobs G. Dijkstra F, et al. Among authors: asgharnejad m. Transl Psychiatry. 2022 Sep 24;12(1):408. doi: 10.1038/s41398-022-02148-w. Transl Psychiatry. 2022. PMID: 36153330 Free PMC article. Clinical Trial.
46 results